PeproStat as a Topical Agent Used to Stop Bleeding in Patients Undergoing Surgery

Bleeding Clinical Trial

Official title:

A Controlled, Randomized, Multi-centre, Double Blind, Phase II Study to Evaluate Efficacy and Safety of Topical PeproStat in Intraoperative Surgical Haemostasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03131336
• Other study ID #: HX-02-PEP
• Status: Completed
• Phase: Phase 2
• First received: March 27, 2017
• Last updated: February 26, 2018
• Start date: March 31, 2017
• Est. completion date: October 11, 2017

Study information

• Verified date: February 2018
• Source: Haemostatix Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the effectiveness and safety of a new peptide-based coagulant, PeproStat. The study drug will be applied to patients undergoing liver/soft tissue surgery, vascular surgery or spine surgery. The speed of action of the new coagulant, that is applied with a gelatin sponge, will be compared to the same sponge but with saline (a commonly used standard of care).

Description:

PeproStat is a new class of topical haemostatic agent composed of recombinant human albumin (rHA) conjugated with fibrinogen-binding peptides. The conjugate polymerises fibrinogen into a fibrin-like clot without the need for thrombin.

PeproStat is formulated in a liquid, and is soaked into a haemostatic gelatin sponge in the operating theatre, and applied directly to the site of bleeding. The gelatin sponge (Spongostan ) is an approved "passive" haemostat i.e., PeproStat is an adjunct to a passive haemostat.

The study is designed in a 2:1 randomization (verum:placebo) to investigate the efficacy in terms of Time to hemostasis, mean (mTTH) at the primary target bleed site (TBS), measured in minutes (min) from the start of treatment application (TxStart) at the TBS to the achievement of hemostasis at that site or to the end of the 10-minute assessment period if hemostasis has not yet been achieved.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 169
• Est. completion date: October 11, 2017
• Est. primary completion date: August 23, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria: At screening and baseline:

1. Subject is undergoing a planned open liver/soft tissue surgery, vascular surgery or spine surgery.

2. Subjects are able and willing to provide written informed consent to participate in this study.

3. Adult males and females =18 years of age at screening.

4. Willing and able to comply with all protocol requirements including follow-up assessments.

5. Male subjects must be willing and able to use adequate contraception from enrollment through to the 30 day follow-up visit.

6. Women of childbearing potential (WCBP)C have to use highly effective methods of contraception from enrollment through to the 30 day follow-up visit.

Intraoperative:

7. The subject presents an identified target bleeding site with mild or moderate bleeding, which conventional surgical techniques are insufficient to control or are inappropriate and would otherwise be a candidate for standard haemostats.

8. The subject presents no intraoperative complications, other than bleeding, that may interfere with study assessments as judged by the Investigator.

9. The subject presents no contaminated areas of the body, signs of infection or abscess development.

10. Total target bleeding site surface area of = 70 cm2, defined within one or two TBSs.

Exclusion Criteria:

1. Subject is undergoing emergency surgical procedure.

2. Use of study treatment and sponge in

• Closure of skin incisions as the sponge may interfere with the healing of skin edges.

• Intravascular compartments because of the risk of embolization following sponge application.

3. Recipient of an organ transplant.

4. Haematologic, biochemistry and coagulation panel thresholds at screening:

• Haemoglobin = 9.0 g/dL.

• Platelet count =100,000/mm3 (= 100 x 109/L).

• International Normalized Ratio (INR) > 2.0 or activated Partial Thromboplastin Time (aPTT) ratio > 2.0.

• Fibrinogen level < 1.5 g/L.

• Aspartate Aminotransferase (AST) or Alanine aminotransferase (ALT) = 3 times the upper limit normal range, except for subjects undergoing liver resection surgery where there is no upper limit for these analytes due to the nature of their disease.

5. Severe renal failure.

6. Any other disease or condition that may affect normal blood clotting, for example thrombocytopenia, as judged by the Investigator.

7. A known history of anaphylaxis or allergic reaction to human albumin, PEGylated proteins, yeast or moulds, porcine products or other components in the study medication or sponge.

8. Participation in another investigational drug or device research study within 30 days before and after enrolment in the current study.

9. Current known or suspected alcohol and/or drug abuse or dependence at the time of screening.

10. Any concurrent medical, surgical, or psychiatric condition that may, in the Investigator's opinion, affect the subject's willingness or ability to meet all study requirements during the study duration.

11. Known HIV, Hepatitis B virus or Hepatitis C Virus infection.

12. During the surgery, subject presents severe bleeding where use of a topical haemostat would be inappropriate.

13. Anti-platelets/oral anticoagulants treatment:

1. Soft tissue/liver and neurosurgery: Subject is taking anti-platelet agents or oral anticoagulants within 7 days of surgery

2. Vascular surgery: Subject is taking dual anti-platelet treatment or oral anticoagulants within 7 days of surgery. One anti-platelet agent is allowed perioperatively.

14. Heparin treatment:

c. Soft tissue/liver and neurosurgery only: Subject is receiving therapeutic doses of heparin perioperatively. Only prophylactic Low Molecular Weight Heparin is allowed.

15. Pregnant or breast-feeding subject.

Related Conditions & MeSH terms

• Bleeding
• Hemorrhage

Intervention

Drug:
• PeproStat
solution for local application
• Saline
solution for local application

Locations

Country	Name	City	State
Bosnia and Herzegovina	University Clinical Hospital, Bolnicka 25	Sarajevo
Croatia	University Clinical Hospital Centre "Sestre Milosrdnice", Vinogradska cesta 29	Zagreb
Poland	Klinika Neurochirurgii Gdanskie Centrum Kliniczne, ul. Debinki 7	Gdansk
Serbia	Clinical centre of Serbia, Clinic for vascular and endovascular surgery, Koste Todorovica Street 8	Belgrade
United Kingdom	Addenbrookes Hospital	Cambridge

Sponsors (1)

Lead Sponsor	Collaborator
Haemostatix Ltd

Countries where clinical trial is conducted

Bosnia and Herzegovina,  Croatia,  Poland,  Serbia,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The difference in time to hemostasis in minutes when using verum vs placebo	Efficacy in terms of Time to hemostasis, mean (mTTH) at the primary target bleed site (TBS),measured in minutes from the start of treatment application (TxStart) at the TBS to the achievement of haemostasis at that site or to the end of the 10-minute assessment period if haemostasis has not yet been achieved.	10 minutes after application
Secondary	Percentage of subjects achieving hemostasis at 1 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics	Percentage of subjects achieving haemostasis within 1 minute from application of treatment	1 minute after start of treatment
Secondary	Percentage of subjects achieving hemostasis at 2 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics	Percentage of subjects achieving haemostasis within 2 minutes from application of treatment	2 minutes after start of treatment
Secondary	Percentage of subjects achieving hemostasis at 3 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics	Percentage of subjects achieving haemostasis within 3 minutes from application of treatment	3 minutes after start of treatment
Secondary	Percentage of subjects achieving hemostasis at 5 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics	Percentage of subjects achieving haemostasis within 5 minutes from application of treatment	5 minutes after start of treatment
Secondary	Percentage of subjects achieving hemostasis at 7 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics	Percentage of subjects achieving haemostasis within 7 minutes from application of treatment	7 minutes after start of treatment
Secondary	Percentage of subjects achieving hemostasis at 10 min haemostasis in adult subjects undergoing open liver/soft tissue, vascular and spine surgery using descriptive statistics	Percentage of subjects achieving haemostasis within 10 minutes from application of treatment	10 minutes after start of treatment
Secondary	Median time to hemostasis in minutes from TxStart to the achievement of hemostasis or to the end of the 10-minute assessment period if hemostasis has not yet been achieved	Median time for haemostasis to be achieved	10 minutes after start of treatment
Secondary	Number/rate of subjects who do not achieve hemostasis within 10 min	Number/rate of subjects who do not achieve hemostasis within 10 min	10 minutes after start of treatment
Secondary	Number of sponges applied at Target Bleeding Site (TBS)	Number of sponges used at TBS, 1 or 2	Counted on Day of surgery
Secondary	Dose of PeproStat determined by number and size (if cut to size) of PeproStat soaked sponges applied at TBS	Dose of PeproStat determined by number and size (if cut to size) of PeproStat soaked sponges applied at TBS	Measured on day of surgery
Secondary	Number/rate of treatment failures	Number of participants not achieving haemostasis within 10 minutes at primary, secondary or both TBS's	10 minutes after start of treatment
Secondary	Use of alternative haemostatic agents at the TBS	Number of participants requiring use of other haemostats at the TBS	Documented on the day of surgery
Secondary	Investigator assessment of efficacy to obtain haemostasis	Investigator's assessment of the efficacy of the treatment with a score of 1-5, where 5 is very effective	Documented on the day of surgery
Secondary	Investigator assessment ease of use of study treatment	Investigator assessment ease of use of study treatment with a score of 1-5, where 5 is very effective	Documented on the day of surgery
Secondary	Adverse Events	Number of Adverse Events (AEs) including adverse events of special interest: Bleeding at the TBS after 10-minute assessment period during or after surgery (if re-operation is required) and transfusion requirement	Measured from the point of consent to Day 30
Secondary	Heparin usage	Number of participants with Heparin usage	Measured from the point of consent to Day 30
Secondary	Antiplatelet usage	Number of participants with Antiplatelet usage	Measured from the point of consent to Day 30
Secondary	Laboratory safety parameters	Changes in Laboratory safety parameters at day 5 vs. screening	Measured at Day 5
Secondary	Laboratory safety parameters	Laboratory safety parameters at day 30 vs. screening	Measured at screening, Day 30
Secondary	Immunogenicity testing	Immunogenicity testing	Measured at screening and Day 30
Secondary	Vital signs	Changes in vital signs	Measured before surgery vs. screening
Secondary	Vital signs	Changes in vital signs	Measured during surgery (before treatment) vs. screening
Secondary	Vital signs	Changes in vital signs	Measured during surgery (15 minutes after treatment) vs. screening
Secondary	Vital signs	Changes in vital signs	Measured at 4 hours after surgery vs. screening
Secondary	Vital signs	Changes in vital signs	Measured at 8 hours after surgery vs. screening
Secondary	Vital signs	Changes in vital signs	Measured at 16 hours after surgery vs. screening
Secondary	12-lead electrocardiogram	Abnormalities in 12-lead electrocardiogram	measured at Day 5
Secondary	12-lead electrocardiogram	Abnormalities in 12-lead electrocardiogram	measured at Day 30 (if medically indicated)